Sugi Predict

Sugi Predict / Targets / GNPAT

GNPAT

Dihydroxyacetone phosphate acyltransferase · O15228 · GNPAT on Sugi Atlas →

8,404 patent compounds predicted against GNPAT, 5,907 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL159459 SCHEMBL159459 0.55 3/20
SCHEMBL159460 SCHEMBL159460 0.55 3/20
SCHEMBL159461 SCHEMBL159461 0.55 3/20
SCHEMBL3027984 SCHEMBL3027984 0.50 3/20
SCHEMBL538658 SCHEMBL538658 0.61 2/20
SCHEMBL2248726 SCHEMBL2248726 0.57 2/20
SCHEMBL1243885 SCHEMBL1243885 0.55 2/20
SCHEMBL1243890 SCHEMBL1243890 0.55 2/20
SCHEMBL20529 SCHEMBL20529 0.54 2/20
SCHEMBL20530 SCHEMBL20530 0.54 2/20
SCHEMBL919220 SCHEMBL919220 0.54 2/20
SCHEMBL1764511 SCHEMBL1764511 0.54 2/20
SCHEMBL1764514 SCHEMBL1764514 0.54 2/20
SCHEMBL1718474 SCHEMBL1718474 0.53 2/20
SCHEMBL1272601 SCHEMBL1272601 0.53 2/20
SCHEMBL1272606 SCHEMBL1272606 0.53 2/20
SCHEMBL137690 SCHEMBL137690 0.53 2/20
SCHEMBL243250 SCHEMBL243250 0.53 2/20
Isospaglumic Acid Isospaglumic Acid (SCHEMBL1649777) 0.52 2/20
SCHEMBL3381459 SCHEMBL3381459 0.52 2/20

Clinical trials — most relevant to GNPAT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging PHASE4COMPLETED
Bezafibrate Trial in CPT2 Deficiency PHASE3UNKNOWN
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
RCDP Natural History Study nanUNKNOWN
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases nanCOMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Intervention and Outcomes in Duarte Galactosemia nanCOMPLETED
Genetic and Metabolic Disease in Children nanRECRUITING
Identification and Characterization of Monogenic Diabetes nanCOMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Health Impacts of Sustainable Ingredient Selection in the Food and Drink Industry - ALTERNATIVE PROTEIN STUDY nanCOMPLETED
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN
Epidemiology of Atherosclerosis nanCOMPLETED
Natural History of GACI With or Without ARHR2 or PXE nanUNKNOWN
The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes nanCOMPLETED
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients. nanCOMPLETED
Exome Sequencing for Atypical Femoral Fractures nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Hypophosphatemic Rickets in Norway nanUNKNOWN
A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a GNPAT binder may also engage these)

ProteinNameSimilarity
G1SPE9 — 1.000 G1SPE9 →
A4IF87 — 1.000 A4IF87 →
P98192 — 0.999 P98192 →
Q9ES71 — 0.997 Q9ES71 →
PARP4 Protein mono-ADP-ribosyltransferase PARP4 0.973 landscape →
F1ND48 — 0.971 F1ND48 →
Q5R5S1 — 0.971 Q5R5S1 →
Q1LWG4 — 0.970 Q1LWG4 →
Q8S8S2 — 0.970 Q8S8S2 →
Q8BYI6 — 0.970 Q8BYI6 →
E9Q4Z2 — 0.970 E9Q4Z2 →
O94952 — 0.969 O94952 →
O93479 — 0.969 O93479 →
Q9D1E8 — 0.969 Q9D1E8 →
Q7L5N7 — 0.968 Q7L5N7 →
Q9ER88 — 0.968 Q9ER88 →
Q5R6S0 — 0.968 Q5R6S0 →
Q641K1 — 0.968 Q641K1 →
Q5ZJV4 — 0.968 Q5ZJV4 →
Q96MI9 — 0.968 Q96MI9 →
P82922 — 0.967 P82922 →
Q9NX78 — 0.967 Q9NX78 →
ABHD16A Phosphatidylserine lipase ABHD16A 0.967 landscape →
Q8VDH1 — 0.967 Q8VDH1 →
Q9NXN4 — 0.967 Q9NXN4 →
Q6MG55 — 0.967 Q6MG55 →
GTF3C3 General transcription factor 3C polypeptide 3 0.967 landscape →
Q14CH1 — 0.967 Q14CH1 →
Q9UPR0 — 0.967 Q9UPR0 →
Q08CZ0 — 0.967 Q08CZ0 →